Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | The impact of immuno-oncology on ALL outcomes

Talha Badar • 2 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia Antibodies Blinatumomab Inotuzumab ozogamicin

Talha Badar, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the impact of immuno-oncology on acute lymphoblastic leukemia (ALL) outcomes, highlighting agents such as blinatumomab and inotuzumab ozogamicin. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Talha Badar

4:38
Blinatumomab vs inotuzumab ozogamicin for ALL
Talha Badar • 2 Jun 2020
3:17
Trends in post-relapse survival in Hodgkin lymphoma
Talha Badar • 3 Jun 2020

Related Videos

1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals